Disability

CEFALY Technology Introduces CEFALY@Work: A Workplace Wellness Initiative for Employees With Migraine

DARIEN, Conn., May 27, 2025 /PRNewswire/ -- Medical device maker CEFALY Technology today announced the launch of CEFALY@Work, a new offering…

8 months ago

CMHA National launches flexible mental health training for managers, ready for your LMS

TORONTO, May 27, 2025 /CNW/ - To meet the growing need for mental health training in workplaces, the Canadian Mental Health…

8 months ago

Route 92 Medical Announces Results of SUMMIT MAX Clinical Trial Showing Highest First Pass Effect Ever Reported in a Randomized Endovascular Stroke Thrombectomy Study

Data from 250-patient, 31-center, randomized controlled trial presented at European Stroke Organisation Conference Three highest enrolling sites reported 96% delivery…

9 months ago

From Affordable Premiums to Holistic Care, Policybazaar Unveils Comprehensive Solutions for NRIs and Their Families in India

GURUGRAM, India, May 16, 2025 /PRNewswire/ -- Policybazaar, one of India's largest online insurance platforms, has launched, through its insurance…

9 months ago

accessiBe Forms Advisory Board and Testing Hub Comprised of Community Leaders and Disability Advocates to Drive Web Accessibility Product Innovation

Advisory Groups Launch on Global Accessibility Awareness Day (GAAD) NEW YORK, May 15, 2025 /PRNewswire/ -- Web accessibility market leader accessiBe,…

9 months ago

CEFALY to Demonstrate Its Migraine Treatment Device at the American College of Obstetricians and Gynecologists’ Annual Clinical & Scientific Meeting

DARIEN, Conn., May 13, 2025 /PRNewswire/ -- Medical device maker CEFALY Technology will be conducting live demonstrations of its clinically…

9 months ago

$101M XPRIZE HEALTHSPAN AWARDS FIRST MILESTONE WINNERS DRIVING TOWARD REVOLUTIONARY HEALTHY AGING ADVANCES

Over 600 competing teams from 58 countries entered global competition. Teams with a broad range of potential solutions for healthspan…

9 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes…

9 months ago